Safety Shot Management

Management criteria checks 0/4

Safety Shot's CEO is Jarrett Boon, appointed in Feb 2024, has a tenure of less than a year. directly owns 2.05% of the company’s shares, worth $905.62K. The average tenure of the management team and the board of directors is 0.8 years and 1.4 years respectively.

Key information

Jarrett Boon

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	2.0%
Management average tenure	less than a year
Board average tenure	1.4yrs

Recent management updates

Recent updates

Jupiter Wellness inks exclusive licensing deal with Rejoy for new prescription products

Sep 20

Jupiter Wellness agrees with drug developer to refrain from exercising convertible note rights

Jul 26

Jupiter Wellness says developing a new women’s sexual health product

Jul 06

Jupiter Wellness: Advancing CBD-Based Medical Therapeutics And Wellness Products

Nov 30

CEO

Jarrett Boon (57 yo)

less than a year

Tenure

Mr. Jarrett Boon was Advisory Board Member of Mangoceuticals, Inc since January 06, 2023. He serves as Director at Safety Shot, Inc. (formerly known as Jupiter Wellness, Inc.) since October 10, 2023 and se...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jarrett Boon	CEO & Director	less than a year	no data	2.05% $ 905.6k
Jordan Schur	President & Director	less than a year	no data	0.41% $ 181.1k
Danielle Rosa-Diaz	Chief Financial Officer	less than a year	no data	0% $ 0
David Sandler	Chief Operating Officer	less than a year	no data	0% $ 0
Anthony Pedicelli	Director of Marketing	1.7yrs	no data	no data
Andy Goren	Chief Medical Officer & Member of Scientific Advisory Board	2.5yrs	no data	no data
Josh Wagner	Chief Revenue Officer	1.4yrs	no data	no data

0.8yrs

Average Tenure

52yo

Average Age

Experienced Management: SHOT's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Jarrett Boon	CEO & Director	1.2yrs	no data	2.05% $ 905.6k
Jordan Schur	President & Director	less than a year	no data	0.41% $ 181.1k
Andy Goren	Chief Medical Officer & Member of Scientific Advisory Board	3.4yrs	no data	no data
Hector Alila	Member of Scientific Advisory Board	2.3yrs	US$25.00k	0% $ 0
Christopher Melton	Independent Director	5.3yrs	US$25.00k	0.10% $ 45.3k
Jack Brewer	Member of Advisory Board	1.3yrs	no data	no data
Richard Pascucci	Member of Advisory Board & Director	1.4yrs	no data	0% $ 0
Miklos Gulyas	Independent Chairman	1.4yrs	no data	2.05% $ 905.6k
David Long	Independent Director & Member of Advisory Board	1.3yrs	no data	0% $ 0

1.4yrs

Average Tenure

52yo

Average Age

Experienced Board: SHOT's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 07:46
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Safety Shot, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ishan Majumdar	Baptista Research

Safety Shot Management

Management criteria checks 0/4

Key information

Recent management updates

Independent Director exercised options and sold US$57m worth of stock

Safety Shot, Inc., Annual General Meeting, Jul 31, 2024

Safety Shot, Inc. Appoints David J. Long to the Board of Directors

Safety Shot, Inc Appoints Jordan Schur as President and Company Board Member

Safety Shot, Inc. Announces Chief Executive Officer Changes

Safety Shot, Inc. Appoints Danielle De Rosa as Chief Financial Officer, Effective March 1,2024

Recent updates

Independent Director exercised options and sold US$57m worth of stock

Safety Shot, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Safety Shot, Inc. has filed a Follow-on Equity Offering in the amount of $0.49829 million.

Third quarter 2024 earnings released: US$0.21 loss per share (vs US$0.26 loss in 3Q 2023)

Safety Shot, Inc. Announces the Launch of Its Newly Rebranded and Reformulated Alcohol-Reducing Beverage, Sure Shot

Safety Shot, Inc. Rebrands as Sure Shot and Unveils a Bold New Look, Focusing on 4-Ounce Bottles and Powder Stick Packs

New major risk - Share price stability

Safety Shot, Inc. announced that it has received $3.421346 million in funding from Core 4 Capital Corp.

Safety Shot Clinical Data Results Confirm Breakthrough in Dramatic Reduction of Morning-After Symptoms Associated with Excessive Drinking

Health Check: How Prudently Does Safety Shot (NASDAQ:SHOT) Use Debt?

New major risk - Financial position

Safety Shot, Inc. to Release On-the-Go Powder Stick Packs of the First Alcohol Reducing Product

Safety Shot, Inc. announced that it expects to receive $1 million in funding

Safety Shot, Inc., Annual General Meeting, Jul 31, 2024

Safety Shot, Inc. Launch of Revolutionary Formula in New, Convenient 4-Ounce Bottles

First quarter 2024 earnings released: US$0.33 loss per share (vs US$0.051 loss in 1Q 2023)

Safety Shot, Inc. has filed a Follow-on Equity Offering in the amount of $4.999999 million.

New major risk - Revenue size

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.70 loss in FY 2022)

Safety Shot, Inc. Appoints David J. Long to the Board of Directors

Safety Shot, Inc Appoints Jordan Schur as President and Company Board Member

Is Safety Shot (NASDAQ:SHOT) Using Debt In A Risky Way?

New minor risk - Market cap size

Safety Shot, Inc. Announces Chief Executive Officer Changes

Safety Shot, Inc. Appoints Danielle De Rosa as Chief Financial Officer, Effective March 1,2024

Less than half of directors are independent

Safety Shot Appoints Rich Pascucci to Its Board of Directors

Safety Shot, Inc. Announces West Coast Launch of Safety Shot

Safety Shot, Inc. announced delayed 10-Q filing

New major risk - Shareholder dilution

Safety Shot, Inc., Annual General Meeting, Dec 05, 2023

Safety Shot Inc. Announces Direct-To-Consumer Launch of Safety Shot

Safety Shot, Inc. Appoints Jarrett Boon to its Board of Directors

The Honorable Jack Brewer, M.Ed. Joins Safety Shot’s Advisory Board

Jupiter Wellness Appoints Jarrett Boon as COO

Jupiter Wellness Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Jupiter Wellness, Inc. Announces Chief Financial Officer Changes

Second quarter 2023 earnings released: US$0.013 loss per share (vs US$0.066 loss in 2Q 2022)

Jupiter Wellness, Inc. Appoints David Long to its Advisory Board

Jupiter Wellness, Inc Announces Board Appointments

Jupiter Wellness, Inc. Announces Executive Changes

New major risk - Share price stability

Jupiter Wellness, Inc. (NasdaqCM:JUPW) agreed to acquire Assets of GBB Drink Lab Inc.

First quarter 2023 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2022)

Full year 2022 earnings released: US$0.69 loss per share (vs US$1.69 loss in FY 2021)

Jupiter Wellness, Inc. Appoints Hector Alila as Additional Director

Jupiter Wellness, Inc., Annual General Meeting, Dec 22, 2022

Jupiter Wellness Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jupiter Wellness Regains Compliance with Nasdaq Minimum Bid Price Requirement

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.24 loss in 3Q 2021)

Less than half of directors are independent

Jupiter Wellness, Inc. Re-Opens Enrollment in Clinical Trial Comparison of JW-100 and EUCRISA for the Treatment of Eczema

Director recently bought US$105k worth of stock

Jupiter Wellness, Inc. Initiates Clinical Trial for Potential New Treatment for Tinnitus

Jupiter Wellness to get US patent for minoxidil use in hair loss disorder

Jupiter Wellness inks exclusive licensing deal with Rejoy for new prescription products

Jupiter Wellness, Inc. Announces Board Changes, Effective September 15, 2022

Second quarter 2022 earnings released: US$0.066 loss per share (vs US$0.36 loss in 2Q 2021)

Jupiter Wellness agrees with drug developer to refrain from exercising convertible note rights

Jupiter Wellness says developing a new women’s sexual health product

Jupiter Wellness Receives Non-Compliance Notice from Nasdaq Related to Listing Rule 5635(c)

Jupiter Wellness Receives Non-Compliance Letter from Nasdaq

Jupiter Wellness, Inc. Appoints Prof. Andy Goren, MD as Chief Medical Officer

Jupiter Wellness, Inc. (NasdaqCM:JUPW) acquired Assets from Applied Biology, Inc. on June 21, 2022.

First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: US$1.69 loss per share (vs US$0.86 loss in FY 2020)

Jupiter Wellness, Inc. Announces Resignation of Ryan Allison as Chief Operating Officer

Less than half of directors are independent